Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

BACKGROUND: Approximately 20% of melanomas contain a mutation in NRAS. However no direct inhibitor of NRAS is available. One of the main signaling pathways downstream of NRAS is the MAPK pathway. In this study we investigated the possibility of blocking oncogenic signaling of NRAS by inhibiting two...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Cancer
Autori principali: Atefi, Mohammad, Titz, Bjoern, Avramis, Earl, Ng, Charles, Wong, Deborah JL, Lassen, Amanda, Cerniglia, Michael, Escuin-Ordinas, Helena, Foulad, David, Comin-Anduix, Begonya, Graeber, Thomas G, Ribas, Antoni
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2015
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4320814/
https://ncbi.nlm.nih.gov/pubmed/25645078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-015-0293-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi